Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silo Pharma (SILO) Non-Current Deffered Revenue (2021 - 2025)

Historic Non-Current Deffered Revenue for Silo Pharma (SILO) over the last 5 years, with Q3 2025 value amounting to $667502.0.

  • Silo Pharma's Non-Current Deffered Revenue fell 974.87% to $667502.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $667502.0, marking a year-over-year decrease of 974.87%. This contributed to the annual value of $721578.0 for FY2024, which is 908.45% down from last year.
  • Silo Pharma's Non-Current Deffered Revenue amounted to $667502.0 in Q3 2025, which was down 974.87% from $685527.0 recorded in Q2 2025.
  • Over the past 5 years, Silo Pharma's Non-Current Deffered Revenue peaked at $973935.0 during Q2 2021, and registered a low of $667502.0 during Q3 2025.
  • Over the past 5 years, Silo Pharma's median Non-Current Deffered Revenue value was $829731.0 (recorded in 2023), while the average stood at $827275.9.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first crashed by 269.26% in 2022, then plummeted by 974.87% in 2025.
  • Quarter analysis of 5 years shows Silo Pharma's Non-Current Deffered Revenue stood at $937884.0 in 2021, then fell by 7.69% to $865782.0 in 2022, then decreased by 8.33% to $793680.0 in 2023, then fell by 9.08% to $721578.0 in 2024, then fell by 7.49% to $667502.0 in 2025.
  • Its Non-Current Deffered Revenue stands at $667502.0 for Q3 2025, versus $685527.0 for Q2 2025 and $703553.0 for Q1 2025.